Skeletal muscle as an artificial endocrine tissue

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 17, Issue 2, 2003, Pages 211-222

  Goldspink, Geoffrey ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Gene transfer; Growth factors; Hormones; Muscle specific expression; Paracrine

Indexed keywords

ERYTHROPOIETIN; GENE PRODUCT; GROWTH FACTOR; GROWTH HORMONE; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; PEPTIDE; PLASMID VECTOR; PROTEIN; SOMATOMEDIN; VASCULOTROPIN; VIRUS VECTOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT VASCULOTROPIN;

BACULOVIRUS EXPRESSION SYSTEM; BIOREACTOR; DIABETIC NEUROPATHY; DRUG HALF LIFE; ENDOCRINE FUNCTION; ERYTHROPOIESIS; GENE CONSTRUCT; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSFECTION; GROWTH HORMONE DEFICIENCY; HUMAN; HUMAN TISSUE; MITOSIS; MYOBLAST; NONHUMAN; PARACRINE SIGNALING; PERIPHERAL VASCULAR DISEASE; REVIEW; SECRETORY CELL; SKELETAL MUSCLE; SYSTEMIC CIRCULATION; ANEMIA; CELL TRANSFER; ENDOCRINE SYSTEM; GENE CONTROL; GENE VECTOR; HORMONE RELEASE; HORMONE SYNTHESIS; IMMUNOGENICITY; MUSCLE FUNCTION; PROTEIN DEFICIENCY; TRANSGENE;

EID: 0038715419     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-690X(03)00015-0     Document Type: Review

References (68)

1. Wolfe JA, Malone RW, Williams P et al. Direct-gene transfer into mouse muscle in vivo. Science 1990; 247: 1466-1468.
2. Hasse G, Kennel P, Vigne E et al. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nature Medicine 1996; 3: 429-436.
3. Tripathy SK, Goldwasser E, Lu MM et al. Stable delivery of physiological levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-deficient adenovirus. Proceedings of the National Academy of Sciences of the USA 1994; 91: 11557-11561.
4. Fischman D. Development of striated muscle. In Bourne GH (ed.) The Structure and Function of Muscle, 2nd edn. New York: Academic Press, 1972, pp 75-142.
5. Yao SN, Wilson JM, Nabel EG et al. Expression of human factor IX in rat capillary endothelial cells; Toward somatic gene therapy for haemophilia B. Proceedings of the National Academy of Sciences of the USA 1991; 88: 8101-8105.
6. Danko I & Wolff JA. Direct gene-transfer into muscle. Vaccine 1994; 12: 1499-1502.
7. Feldman LJ, Tahlil O & Steg G. Perspectives of arterial gene-therapy for the prevention of restenosis. Cardiovascular Research 1996; 32: 194-207.
8. Rothman T, Katus HA, Hartong R et al. Heart muscle-specific gene-expression using replication-defective recombinant adenovirus. Gene Therapy 1996; 3: 919-926.
9. Gorecki DC & MacDermott KD. Gene therapy: Panacea or placebo? Main application of gene therapy. Archivum Immunologiae et Therapiae Experimentalis 1997; 45: 367-374.
10. Vile RG, Sunassee K & Diaz RM. Strategies for achieving multiple layers of selectivity in gene therapy. Molecular Medicine 1998; 4: 84-92.
11. Yang Y, Haeker SE, Su Q & Wilson JM. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Human Molecular Genetics 1996; 5: 1703-1712.
12. Fisher KJ, Jooss K, Alston J et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Medicine 1997; 3: 306-312.
13. Yeh P & Perricaudet M. Advances in adenoviral vectors from genetic engineering to their biology. FASEB Journal 1997; 11: 615-623.
14. Check E. Gene therapy: A tragic setback. Nature 2002; 420: 116-118.
15. Davis HL, Demeneix BA, Quantin B et al. Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Human Gene Therapy 1993; 4: 733-740.
16. Gregoriadis G, Saffie R & DeSouza JB. Liposome-mediated DNA vaccination. FEBS Letters 1997; 402: 107-110.
17. Mumper RJ, Wang JJ, Klakamp SL et al. Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle. Journal of Controlled Release 1998; 52: 191-203.
18. Aihara H & Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nature Biotechnology 1998; 16: 867-870.
19. Wang J-M, Zheng H, Sugahara Y et al. Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells. Human Gene Therapy 1996; 7: 1743-1756.
20. Novo FJ, Gorecki DC, Goldspink G & MacDermott KD. Gene transfer and expression of human alpha-galactosidase from mouse muscle in vitro and in vivo. Gene Therapy 1997; 4: 488-492.
21. Rivera VM, Clackson T, Natesan S et al. A humanized system for pharmacological control of gene expression. Nature Medicine 1996; 2: 1028-1032.
22. Bohl D, Naffiakh N & Heard JM. Long term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nature Medicine 1997; 3: 299-305.
23. Pin CL & Merrifield PA. Developmental potential of rat L6 myoblasts in vivo following injection into regenerating muscles. Developmental Biology 1997; 188: 147-166.
24. MacColl G, Novo J, Marshall N et al. A method for producing biologically active growth hormone in muscle cells. Journal of Endocrinology 1998; 156: OC20.
25. Blue-Pajot MT, Epelbaum J, Gourj D et al. Hypothalamic and hypophyseal regulation of growth hormone secretion. Cellular and Molecular Neurobiology 1998; 18: 101-123.
26. Al-Hendy A, Hortelano G, Tannenbaum GS & Chang PL. Correction of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts - An alternative approach to somatic gene-therapy. Human Gene Therapy 1995; 6: 165-175.
27. Hahn TM, Copeland KC & Woo SLC. Phenotypic correction of dwarfism by constitutive expression of growth hormone. Endocrinology 1996; 137: 4988-4993.
28. Draghia-Akli R, Li X & Schwartz RJ. Enhanced growth by ectopic expression of growth hormone releasing hormone using an injectable myogenic vector. Nature Biotechnology 1997; 15: 1285-1289.
29. Anwer K, Shi M, French MF et al. Systemic effect of human growth hormone after intramuscular injection of a single dose of muscle-specific gene medicine. Human Gene Therapy 1998; 9: 959-970.
30. Skarli M, Kiri A, Vrbova G et al. Myosin regulatory elements as vectors for gene transfer by intramuscular injection. Gene Therapy 1998; 5: 514-520.
31. Ng ST, Zhou JA, Adesanya OO et al. Growth hormone treatment induces mammary gland hyperplasia in ageing. Nature Medicine 1997; 3: 1141-1149.
32. Goldspink G. Methods of treating muscular disorders. United States Patent No: US 6,211,842 BI Apr 24 2001.
33. Barton-Davies ER, Shoturma DI, Musaro A et al. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proceedings of the National Academy of Sciences of the USA 1998; 95: 15 603-15 607.
34. Yang SY & Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Letters 2002; 522: 156-160.
35. Ye X, Rivera VM, Zoltick P et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999; 283: 88-91.
36. McGary EC, Rondon IJ & Beckman BS. Post-transcriptional regulation of erythropoietin mRNA stability by erythropoietin mRNA-binding protein. Journal of Biological Chemistry 1997; 272: 8628-8634.
37. Rask CA, Carlsen RC & Elias KA. Site of action of recombinant human nerve growth factor (rhNGF) in diabetic neuropathy appears to be small sensory neurons in the peripheral nervous system; Phase II data support clinical results. Journal of Endocrinology 1998; 156(supplement): P91.
38. Ishii DN & Lupien SB. Insulin-like growth factors protect against diabetic neuropathy - Effects on sensory nerve regeneration in rats. Journal of Neuroscience 1995; 40: 138-144.
39. Apfel SC & Kessler JA. Neurotrophic factors in the treatment of peripheral neuropathy. CIBA Foundation Symposia 1996; 196: 98-108.
40. Lepantalo M & Tukianen E. Combined vascular reconstruction and microvascular muscle flap transfer for salvage of ischemic legs with major tissue loss and wound complications. European Journal of Vascular and Endovascular Surgery 1996; 12: 65-69.
41. Cherwek DH, Hopkins MB, Thompson MJ et al. Fiber type-specific differential expression of angiogenic factors in response to chronic hindlimb ischemia. American Journal of Physiology 2000; 279: H932-H938.
42. Battegay EJ. Angiogenesis-mechanistic insights, neovascular diseases, and therapeutic prospects. Journal of Molecular Medicine 1995; 73: 333-346.
43. Takeshit S, Pu LQ, Stein LA et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of limb ischaemia. Circulation 1994; 90: 228-243.
44. Gabrilovich DI, Chen HL, Cunningham HT et al. Production of vascular endothelial growth-factor by human tumours inhibits the functional maturation of dendritic cells. Nature Medicine 1996; 2: 1096-1103.
45. Oyama T, Ran S, Ishida T et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic cells. Journal of Immunology 1998; 160: 1224-1232.
46. Hu SX, Ji W, Zhou YL et al. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Cancer Research 1997; 57: 3339-3343.
47. Liang X, Hartika J, Sukhu L et al. Novel high expressing and antibiotic controlled plasmid vectors designed for use in gene therapy. Gene Therapy 1996; 5: 350-356.
48. Miller RG, Sharma KR, Pavlath GK, et al. Myoblast implantation in Duchenne muscular dystrophy: The San Francisco study. Muscle and Nerve 1997; 20: 469-478.
49. Floyd SS, Booth DK, Van Deukekom JCT et al. Autologous myoblast transfer: A combination of myoblast transplantation and gene therapy. Basic and Applied Myology 1997; 7: 241-250.
50. Wells DJ & Goldspink G. Age and sex influence expression of plasmid DNA directly injected into mouse skeletal muscle. FEBS Letters 1992; 306: 203-205.
51. Danko I, Williams P, Herweijer H et al. High expression of naked plasmid DNA in muscles of young rodents. Human Molecular Genetics 1997; 6: 1435-1443.
52. Zabner J, Couture LA, Gregory RJ et al. Adenovirus-mediated gene-transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993; 75: 207-216.
53. Kochnake S, Clemens PR, Mitani K et al. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proceedings of the National Academy of Sciences of the USA 1996; 93: 5731-5736.
54. Morsy MA, Gu MC, Motzel S et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of leptin transgene. Proceedings of the National Academy of Sciences of the USA 1998; 95: 7866-7871.
55. Scadding JW & Gibbs J. In Souhami RL & Moxham J (eds) Textbook of Medicine, 2nd edn. Edindburgh: Churchill Livingstone, 1994, pp 858-982.
56. Yang YP, Trinchieri G & Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene-therapy to mouse lung. Nature Medicine 1995; 1: 890-893.
57. Sato Y, Roman M, Tighe H et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunizations. Science 1996; 272: 352-354.
58. Stacy KJ, Sweet MJ & Hume DA. Macrophages ingest and are activated by bacterial DNA. Journal of Immunology 1996; 157: 2116-2122.
59. Roman M, Martin-Orozco E, Goodman JS et al. Immunostimulatory DNA sequences function as T helper-I-promoting adjuvants. Nature Medicine 1997; 3: 849-854.
60. DeVlam K, De Keyser F, Verbruggen G et al. Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clinical and Experimental Rheumatology 1993; 11: 393-397.
61. Wells KE, Maule J, Kingston R et al. Immune responses, not promoter inactivation, are responsible for decreased long-term expression following plasmid gene transfer into skeletal muscle. FEBS Letters 1997; 407: 164-168.
62. Miller G, Steinbrecher RA, Murdock PJ et al. Expression of factor VII by muscle cells in vitro and in vivo following direct gene transfer - Modelling gene therapy for haemophilia. Gene Therapy 1995; 2: 736-742.
63. Tripathy SK, Black HB, Goldwasser E & Leiden M. Immune responses to transgene encoded proteins limit the stability of gene expression after injection of replication defective adenovirus vectors. Nature Medicine 1996; 2: 545-550.
64. Petrof B. The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy. Molecular and Cellular Biochemistry 1998; 179: 111-123.
65. Johnson IP, Skarli M & Goldspink G. Comparison of plasmid and viral DNA for the transfer of genes to motor neurones. Society for Neuroscience Abstracts 1999; 24: 610.6.
66. Chromiak A, Shanksy J, Perrone C & Vandenburgh HH. Bioreactor perfusion system for the long-term maintenance of tissue-engineered skeletal muscle organoids. In Vitro Cellular & Developmental Biology Animal 1998; 34: 694-703.
67. Kosnik PE, Faulkner JA & Dennis RG. Functional development of engineered skeletal muscle from adult and neonatal rats. Tissue Engineering 2001; 7: 573-584.
68. Powell CA, Smiley BL, Mills J & Vandenburgh HH. Mechanical stimulation improves tissue-engineered human skeletal muscle. American Journal of Cell Physiology 2002; 283: C1557-C1565.